Posts belonging to Category Breaking News

2017 HS Scholarship Appliction Deadline extended to May 26th

Available at Scholarships tab above

Ryde4Life Program

We are sharing this information from the Department of Human Services Division of Senior Services One Bergen County Plaza Hackensack, New Jersey 07601 17_0329_Ryde4Life Program Brochure  

2017 Medical Scholarship

Application available by clicking on the link above or the “Scholarships” tab at the top of this page.

ME and the PACE trial in the New York Times

David Tuller and Julie Rehmeyer have published an article in the New York Times about ME and the PACE trial. https://www.nytimes.com/2017/03/18/opinion/sunday/getting-it-wrong-on-chronic-fatigue-syndrome.html?smid=tw-share&_r=0  

#GivingTuesday

This is the season of giving. Tuesday is National Day of Giving! Be a part of #GivingTuesday – DONATE to NJME/CFSA! NJ/MECFSA is a 501(c)(3) non-profit organization. DONATE at http://www.njcfsa.org/donate/ If you prefer there is also https://www.gofundme.com/ArpitaSheth-MyME (funds also go directly to the organization

Scholarships

The 2016 Scholarships have been posted.  Click on the “Scholarships” tab above.  The Medical Scholarship winner and runner-up essays are at that site.

Info from Bateman Horne Center

https://batemanhornecenter.org/assess-orthostatic-intolerance/

Gene Study

Dr. Nancy Klimas’ ME/CFS Gene Study at Nova Southeast University is still seeking patient and healthy volunteers. If you are interested, you can send a message to Helpdesk@njmecfsa.org and we will forward it to the study. More information can be found at https://sharkmedia.nova.edu/m…/ME+CFS+Genes+Study/1_06vh90p0 This is a chance for both patients and healthy volunteers to participate.

Follow-Up to Letter to NIH Director Collins

Read about the encouraging results at: Members of Congress Urge NIH Director Francis Collins to Strengthen Biomedical Research into Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

First Approved ME/CFS Treatment in the World

Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic First Product Approved for ME/CFS Indication Anywhere in the World. Ampligen Approved in Argentina – First in the World 2016-08-23